Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
about
Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia?Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG).Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II studyUpdate on chronic lymphocytic leukemia: overview of new agents and comparative analysis.The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia.FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia.Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyA phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL.Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelModern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroupsCyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 studyPhase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic modelTransplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia and Waldenstrom's MacroglobulinemiaDetailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia.The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia.Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopeniaLong-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome.Management of relapsed chronic lymphocytic leukemia: applying guidelines to practiceChronic lymphocytic leukemia: inception to cure: are we there?Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome.Ibrutinib: a paradigm shift in management of CLL.Demographics, treatment patterns, safety, and real-world effectiveness in patients aged 70 years and over with chronic lymphocytic leukemia receiving bendamustine with or without rituximab: a retrospective study.Chimeric Antigen Receptor T-Cell Therapy for the Community OncologistPhase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.Tailoring of chronic lymphatic leukemia therapyRisk categories and refractory CLL in the era of chemoimmunotherapy.Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia.Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukaemia (CLL) cells involves the lysosomal protease cathepsin BOfatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune CharacteristicsLong-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab.The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies.Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).What do we do with chronic lymphocytic leukemia with 17p deletion?
P2860
Q30407633-C6BA2C25-2575-4E11-86F9-2D8B59DD049FQ33396594-7BD02CFE-C5E7-42E8-9F0D-104F48C0336BQ33401132-BF60E12E-F72C-4D99-ADCE-5D2B82D70479Q33404763-9C7A66B1-F0ED-42D6-B9BC-B212E3ED2F28Q33406478-B9AF61AB-6AC1-43CF-9175-43A8D33FD03CQ33409459-96BB0D0B-747E-41B0-938F-BA9014E49DEEQ33416596-11D905B4-A2CE-42A8-BD2A-3DE56B568ED3Q33429161-3003B3FC-8214-4C7A-B894-3C9974D10BB3Q33438428-B3EFFC6E-FFC4-4D4B-B5D5-DCCD2B5A6447Q33591830-BFDD928D-C407-4C0C-9211-F8717E1204C8Q33794311-27D75A41-9942-42DB-9E05-CB5BB123942FQ33875604-55B294C9-32D3-4DFA-A956-DC3DC69AE00AQ33913537-151A0DE2-67A1-4AA6-8EF0-AC8A7635F835Q34008593-A7DDA6D4-2BD9-46FD-87B1-552951BB049AQ34240404-9FDE5D24-7967-4A1F-96AD-23405DD2B47BQ34269186-BECCE386-1BF6-4E80-902A-ED26BF9AA7ECQ34272532-0498F11B-1A80-4F6A-9E46-27CF377FA8C2Q34625543-0788DE8F-BADB-4F56-9BE7-421F6F9265ECQ35153656-6C69881C-D8C7-4AE3-97B1-5894A2A94C14Q35407650-8661075A-0AC7-405D-AA6D-C33A87670B9EQ35583403-44729707-9A42-4959-BFF5-45D0DD776287Q35951586-565149DD-52D0-4811-A7EC-6C771B2545FCQ36460415-AA33479E-9D74-4607-B069-13654E7E29E2Q36521032-FF31113B-0FE2-48D5-A773-CF02EDE864C1Q36609259-B7F022ED-C72A-42FB-8B5D-D05819D17AF9Q36692782-0B54D5B9-0F93-469D-9523-A0CA3184444FQ36739295-4F73B2A8-EECE-4E5C-B4F7-E5B13AD7551AQ36883352-43AAB63D-8C6C-4044-99E2-4FE0E3CBB39CQ36884399-55A8ED59-71E9-4DE3-8F87-C0B85BA9FBD2Q36929831-E55F478B-AD79-4203-AB57-2BCFF9B9F862Q37127542-91C04D3E-B33A-4DF8-8A56-F263870CAC0CQ37141887-DAE03919-D8F2-496E-BBF8-18B136183F38Q37188389-D1743E96-7383-4D54-A825-728BD72AE250Q37275725-24E76045-71F8-441D-AF30-2D3654CE240EQ37427107-B8AA020E-86C6-4D64-8885-9658620252A2Q37632211-00C8C508-CA37-4F6E-8808-A49DD51EEB7AQ37638782-0B147BF7-6360-4D2F-BCFB-CD28D267D769Q38042439-36E0B7D6-F2A9-432E-839E-5DFCF818EC84Q38061883-87429EDD-49A3-466C-A1EA-EAD4058962ABQ38063170-87CF1071-CEA8-4DEA-8A82-9042CA0D0C16
P2860
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@ast
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@en
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@nl
type
label
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@ast
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@en
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@nl
prefLabel
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@ast
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@en
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@nl
P2093
P2860
P50
P1433
P1476
Fludarabine, cyclophosphamide, ...... or relapsed patients with CLL.
@en
P2093
Charles Koller
Jan Burger
Susan M O'Brien
Xavier C Badoux
Xuemei Wang
P2860
P304
P356
10.1182/BLOOD-2010-08-304683
P407
P577
2011-01-18T00:00:00Z